Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells

Laboratory Investigation

Volumn 92, Issue 2, 2012, Pages 178-190

  Attar Schneider, Oshrat ^a,b   Drucker, Liat ^a,b   Zismanov, Victoria ^a   Tartakover Matalon, Shelly ^a,b   Rashid, Gloria ^a   Lishner, Michael ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

avastin; eIF4E; multiple myeloma; translation initiation; VEGF

Indexed keywords

BEVACIZUMAB; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROTEIN KINASE B; STAT3 PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSLATION INITIATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOPHAGY; CELL CYCLE; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856485226     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.162     Document Type: Article

References (48)

1. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009;374:324-339.
2. Lentzch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004;18:1883-1890. (Pubitemid 39530020)
3. Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003;17:2025-2031. (Pubitemid 37322133)
4. Vincent L, Jin DK, Karajannis MA, et al. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Res 2005;65:3185-3192. (Pubitemid 40524600)
5. Frost P, Shi Y, Lichtenstein A. Akt activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007;26:2255-2262. (Pubitemid 46572812)
6. Gupta D, Treon S, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapuetic applications. Leukemia 2001;15:1950-1961. (Pubitemid 33115003)
7. Podar K, Anderson K. The pathophysiological role of VEGF in hematologic malignancies: therapuetic implications. Blood 2005;105:1383-1395. (Pubitemid 40223651)
8. Barnhart B, Simon M. Taking aim at translation for tumor therapy. J Clin Invest 2007;117:2385-2388. (Pubitemid 47494338)
9. Lin C-J, Cencic R, Mills J, et al. c-Myc and eIF4F are components of a feedforward loop that links transcription to translation. Cancer Res 2008;68:5326-5334.
10. Ramirez-Valle F, Braunstein S, Zavadil J, et al. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 2008;181:293-307. (Pubitemid 351574554)
11. Wu KD, Zhou L, Burtrum D, et al. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007;56:343-357. (Pubitemid 46035904)
12. Montanaro L, Pandolfi P. initiation of mRNA translation in oncogenesis. Cell Cycle 2004;3:1387-1389.
13. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol 2002;55:273-283. (Pubitemid 35193250)
14. Dua K, Williams TM, Beretta L. Translational control of the proteome: relevance to cancer. Proteomics 2001;1:1191-1199.
15. Zismanov V, Lishner M, Tartakover-Matalon S, et al. Tetraspanininduced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer 2009;101:1402-1409.
16. Emlet DR, Brown KA, Kociban DL, et al. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007;6:2664-2674. (Pubitemid 350058147)
17. Weisenthal LM, Patel N, Rueff-Weisenthal C. Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood. J Intern Med 2008;264:275-287.
18. Hasan MR, Ho SH, Owen DA, et al. Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int J Cancer 2011; e-pub ahead of print.
19. Stroikin Y, Dalen H, Lööf S, et al. Inhibition of autophagy with 3-methyladenine results in impaired turnover of lysosomes and accumulation of lipofuscin-like material. Eur J Cell Biol 2004;83:583-590. (Pubitemid 40123822)
20. Drucker L, Afensiev F, Radnay J, et al. Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines. Anticancer Drugs 2004;15:79-84. (Pubitemid 39140176)
21. Lishner M, Zismanov V, Tohami T, et al. Tetraspanins affect myeloma cell fate via Akt signaling and FoxO activation. Cell Signal 2008;20: 2309-2316.
22. Tohami T, Drucker L, Radnay J, et al. Tetraspanin over expression affects multiple myeloma cell survival and invasive potential. FASEB J 2007;21:691-699. (Pubitemid 46348245)
23. Su DF, Xu LP, Miao CY, et al. Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats. Acta Pharmacol Sin 2004;25:148-151.
24. Tugues S, Koch S, Gualandi L, et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88-111.
25. Weisenthal L, Haddy L, Rueff-Weisenthal C. Death of human tumor endothelial cells in vitro through a probable calcium-associated mechanism induced by bevacizumab and detected via a novel method. Nat Precedings 2010; http://hdl:10101/npre.2010.4499.1.
26. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins- understanding properties and mechanisms. Clin Exp Immunol 2009;158(Suppl 1):2-13.
27. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7: 335-345. (Pubitemid 40767935)
28. Mizushima N, Yamamoto A, Hatano M, et al. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 2001;152:657-668.
29. Kuhn DJ, Hunsucker SA, Chen Q, et al. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009;113:4667-4676.
30. Kim JH, Yoon MS, Chen J. Signal transducer and activator of transcription 3 (STAT3) mediates amino acid inhibition of insulin signaling through serine 727 phosphorylation. J Biol Chem 2009;284:35425-35432.
31. Chatterjee M, Jain S, Stuhmer T, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007;109:720-728. (Pubitemid 46105974)
32. Du W, Hattori Y, Hashiguchi A, et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int 2004;54:285-294. (Pubitemid 38716489)
33. Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010;115:2127-3135.
34. Xu X, Vatsyayan J, Gao C, et al. Sumoylation of eIF4E activates mRNA translation. EMBO Rep 2010;11:299-304.
35. Andrieu C, Taieb D, Baylot V, et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 2010;29:1883-1896.
36. Wang X, Proud CG. Methods for studying signal-dependent regulation of translation factor activity. Methods Enzymol 2007;431: 113-142.
37. Murata T, Shimotohno K. Ubiquitination and proteasome-dependent degradation of human eukaryotic translation initiation factor 4E. J Biol Chem 2006;281:20788-20800. (Pubitemid 44115420)
38. Sukarieh R, Sonenberg N, Pelletier J. The eIF4E-binding proteins are modifiers of cytoplasmic eIF4E relocalization during the heat shock response. Am J Physiol Cell Physiol 2009;296:C1207-C1217.
39. Santhanam AN, Bindewald E, Rajasekhar VK, et al. Role of 30UTRs in the translation of mRNAs regulated by oncogenic eIF4E-a computational inference. PLoS One 2009;4:e4868.
40. Ocio EM, Mateos MV, Maiso P, et al. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008;9:1157-1165.
41. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 2007 13 7280-7287.
42. Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 2003;8:337-343. (Pubitemid 36935205)
43. Bellacosa A, Kumar CC, Cristofano AD, et al. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86. (Pubitemid 41202364)
44. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-115. (Pubitemid 29077388)
45. Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/ phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-1539.
46. Lin H-J, Hsieh F-C, Song H, et al. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 2005;93:1372-1381. (Pubitemid 41752864)
47. Song L, Li Y, Shen B. Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNalpha. Cancer Cell Int 2002;2:9.
48. Asnaghi L, Bruno P, Priulla M, et al. mTOR: a protein kinase switching between life and death. Pharmacol Res 2004;50:545-549. (Pubitemid 39388965)